Posted in Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotech, Celgene, Daiichi Sankyo, FDA, Forest Labs, GSK, Genentech, J&J, Johnson and Johnson, Lilly, Medical Devices, Medicine, Merck, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, Red Cross, Sales training, Sanofi-Aventis, Statins, Takeda, tagged alimta, asco, Avastin, herceptin, Millennium, psoriasis, rad001, ranbaxy, s, trasylol, vaptan, vectibix, viagra, xience, zometa on May 16, 2008 | No Comments »
There’s a ton of stuff going on this week, plus we’re in pre-ASCO mode (so lots of oncology news - scroll down for those headlines). Here we go:
What’s a vaptan? Maybe something pretty exciting - A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, [...]
Read Full Post »
This week, it’s time to review AstraZeneca’s home page, in my occasional forays into critiquing the websites of pharmaceutical companies. I don’t do exhaustive site reviews here; just high-level impressions of the home page and the overall navigation design.
When you type www.astrazeneca.com into your browser, you arrive at the home page of the AZ International [...]
Read Full Post »
Posted in AstraZeneca, Bayer, Biotech, Celgene, Cephalon, Daiichi Sankyo, FDA, Forest Labs, GSK, Glaxosmithkline, J&J, Johnson and Johnson, Lilly, Merck, Novartis, Pharma News, Pharmaceutical, Sanofi-Aventis, Schering, tagged alzheimers, Biogen-Idec, Celgene, Eisai, Gleevec, MGI Pharma, Mylan, prasugrel, revlimid, taurel, Treanda, tykerb, Velcade, vytorin, Zevalin on December 18, 2007 | No Comments »
Some interesting oncology results:
Millennium’s Velcade used in combo therapy for multiple myeloma shows impressive results.
Cephalon’s Treanda shows impressive remission numbers for CLL, and effectiveness in non-Hodgins lymphoma (NHL).
Celgene’s Revlimid continues to produce good results at a low-dose regimen.
Novartis‘ Gleevec: effective at halting leukemia progression up to 6 years.
Eisai decides to grab MGI Pharma, and its [...]
Read Full Post »
Posted in AstraZeneca, Cephalon, Friday Collection, J&J, Johnson and Johnson, Medical Devices, Merck, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical on September 6, 2007 | No Comments »
Merck’s new HIV treatment recommended by FDA panel for approval: The advisory panel voted unanimously to recommend marketing approval for the twice-a-day pill, known generically as raltegravir, the first in a novel class of AIDS treatments to go before regulators…more
Pfizer’s spin on Lipitor-switchers called into question: Why did more people die after switching from [...]
Read Full Post »
In a backside-covering move, the FDA has gone public with the “news” that it has nothing to report - yet - about possible heart risks for users of Nexium/Prilosec.
Yes, the FDA caught grief for not going public earlier with some data about Avandia. But what good is accomplished by raising issues like this when the [...]
Read Full Post »
Posted in Amylin, AstraZeneca, Avandia, BMS, Biotech, Celgene, Impactiviti, Lilly, News, Novartis, Oncology, Pfizer, Pharma, Pharma News, Purdue, Schering, Takeda, Wyeth on July 27, 2007 | No Comments »
Two weeks worth of news articles linked here:
Medical News
Actos: safer than Avandia?
Cialis going toward a once-daily version (but shouldn’t it be once every day-and-a-half??)
Novartis gets some approvals in Europe, including new diabetes treatment Galvus
Wyeth’s Pristiq gets stalled by FDA (Pristiq is a cousin of Effexor)
GPC setback on cancer treatment
Promising HIV treatments: competitive upcoming products [...]
Read Full Post »
It’s been quite a slow news week! Most folks are apparently too busy grilling burgers and performing cannonballs off diving boards to release any items of interest.
Here are a few bits scrounged from news sources:
Shire gearing up for Vyvanse (ADHD treatment) launch in the U.S.
AstraZeneca to do the slash job with Medimmune staff.
Novartis and the [...]
Read Full Post »
Posted in AstraZeneca, Avandia, BMS, Bayer, Cephalon, GSK, Glaxosmithkline, J&J, Lilly, Merck, News, Novartis, Pfizer, Pharma News, Pharmaceutical, Scandal, Schering, Takeda on June 29, 2007 | No Comments »
Some robust pipelines: Glaxo Oncology, and J&J.
Cephalon moving more rapidly on oncology candidate Treanda.
Glaxo’s cervical cancer vaccine Cervarix looking good.
Byetta, a diabetes drug from Amylin and Lilly, shows solid results after 3 years of usage.
More good press for Actos, Takeda’s competitor to Avandia.
Cholesterol agents acting against diabetic nerve pain?
Two-pronged approach to treating diabetes - the [...]
Read Full Post »
Fortune magazine, that is. The Whistleblower gets written up for his activities exposing wrongdoing among Big Pharma companies.
Excerpt:
Rost’s many critics would love to be able to dismiss him as an embittered crank. But they can’t. The blog has clout. As a conduit for Big Pharma whistleblowers, it has taken some notable scalps. Earlier this [...]
Read Full Post »
